By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile

 

Viamet Pharmaceuticals 

406 Blackwell Street
Suite 200
Durham  North Carolina  27701-3984  U.S.A.
Phone: 919-969-7505 Fax: n/a


SEARCH JOBS


Industry
Pharmaceutical

Segment
Start Up





Company News
Viamet Pharmaceuticals Announces Initiation Of REVIVE Phase 2b Study Of VT-1161 In Recurrent Vulvovaginal Candidiasis 2/12/2015 8:32:53 AM
Viamet Pharmaceuticals Withdraws $75 Million IPO, Spins Off Cancer Program To Form Innocrin Pharmaceuticals 10/22/2014 6:15:45 AM
Viamet Pharmaceuticals Reels In $60 Million Series D Financing 10/21/2014 5:38:42 AM
Viamet Pharmaceuticals Receives Orphan Drug Designation For VT-1129 9/11/2014 10:11:08 AM
Viamet Pharmaceuticals Announces Appointment Of Amir Tavakkol, Ph.D., As Chief Development Officer 7/22/2014 10:24:59 AM
Viamet Pharmaceuticals Reports Additional Positive Interim Results Of Phase 2 Studies Of VT-1161 With Moderate To Severe Interdigital Tinea Pedis 7/11/2014 11:04:25 AM
Viamet Pharmaceuticals Reports Additional Positive Interim Results Of Phase 2 Study Of VT-1161 In Patients With Moderate To Severe Acute Vulvovaginal Candidiasis 7/11/2014 9:20:05 AM
Durham Drug Developer Viamet Pharmaceuticals Files For $75 Million IPO 7/8/2014 7:22:35 AM
Viamet Pharmaceuticals Reports Positive Interim Results Of Phase 2 Interdigital Tinea Pedis Study Of VT-1161 3/12/2014 8:16:59 AM
Viamet Pharmaceuticals Reports Positive Interim Results Of Phase 2 Study Of VT-1161 2/19/2014 7:20:49 AM
123
//-->